Mairs RJ - Search Results

1

Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.

Mairs RJ, Boyd M. Mairs RJ, et al. Nucl Med Biol. 2008 Aug;35 Suppl 1:S9-20. doi: 10.1016/j.nucmedbio.2008.04.008. Nucl Med Biol. 2008. PMID: 18707637 Review.

2

An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.

Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, Owens J, Vaidyanathan G, Carruthers R, Dorrens J, Zalutsky MR. Boyd M, et al. Among authors: mairs rj. J Gene Med. 2004 Aug;6(8):937-47. doi: 10.1002/jgm.578. J Gene Med. 2004. PMID: 15293352

3

[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.

McCluskey AG, Boyd M, Gaze MN, Mairs RJ. McCluskey AG, et al. Among authors: mairs rj. Cancer Lett. 2005 Oct 18;228(1-2):221-7. doi: 10.1016/j.canlet.2004.11.062. Cancer Lett. 2005. PMID: 15935554 Review.

4

Gene manipulation to enhance MIBG-targeted radionuclide therapy.

Mairs RJ, Fullerton NE, Cosimo E, Boyd M. Mairs RJ, et al. Nucl Med Biol. 2005 Oct;32(7):749-53. doi: 10.1016/j.nucmedbio.2005.03.011. Nucl Med Biol. 2005. PMID: 16243651 Review.

5

Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.

Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, Mairs RJ. Boyd M, et al. Among authors: mairs rj. J Nucl Med. 2006 Jun;47(6):1007-15. J Nucl Med. 2006. PMID: 16741311 Free article.

6

Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.

Fullerton NE, Boyd M, Ross SC, Pimlott SL, Babich J, Kirk D, Zalutsky MR, Mairs RJ. Fullerton NE, et al. Among authors: mairs rj. Med Chem. 2005 Nov;1(6):611-8. doi: 10.2174/157340605774598090. Med Chem. 2005. PMID: 16787344

7

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.

Mairs RJ, Ross SC, McCluskey AG, Boyd M. Mairs RJ, et al. J Nucl Med. 2007 Sep;48(9):1519-26. doi: 10.2967/jnumed.107.042226. Epub 2007 Aug 17. J Nucl Med. 2007. PMID: 17704246 Free article.

8

Radiation quality-dependent bystander effects elicited by targeted radionuclides.

Boyd M, Sorensen A, McCluskey AG, Mairs RJ. Boyd M, et al. Among authors: mairs rj. J Pharm Pharmacol. 2008 Aug;60(8):951-8. doi: 10.1211/jpp.60.8.0002. J Pharm Pharmacol. 2008. PMID: 18644188 Review.

9

Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.

McCluskey AG, Mairs RJ, Tesson M, Pimlott SL, Babich JW, Gaze MN, Champion S, Boyd M. McCluskey AG, et al. Among authors: mairs rj. J Nucl Med. 2012 Jul;53(7):1146-54. doi: 10.2967/jnumed.111.095943. Epub 2012 Jun 11. J Nucl Med. 2012. PMID: 22689924 Free article.

10

Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate.

Fullerton NE, Boyd M, Mairs RJ, Keith WN, Alderwish O, Brown MM, Livingstone A, Kirk D. Fullerton NE, et al. Among authors: mairs rj. Prostate Cancer Prostatic Dis. 2004;7(4):355-63. doi: 10.1038/sj.pcan.4500760. Prostate Cancer Prostatic Dis. 2004. PMID: 15477875

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters